Eli Lilly to Build $6.5 Billion Ingredient-Manufacturing Facility in Texas
By Katherine Hamilton
Eli Lilly said it plans to build a $6.5 billion facility in Houston to make active pharmaceutical ingredients, including a new oral weight-loss drug.
The plant will bring 615 jobs to the Houston area, including engineers and lab technicians, as well as 4,000 construction jobs while it is being built, the company said Tuesday.
Eli Lilly plans to manufacture orforglipron, its first oral, small molecule GLP-1 receptor agonist, at the facility. The company expects to submit orforglipron to global regulatory agencies as a treatment for people with obesity by the end of this year.
The planned site, which is expected to be operational within five years, is the second of four manufacturing sites in the U.S. that the Indianapolis pharmaceutical company plans to announce this year. Earlier this year, the company said it plans to expand its medicine production in the U.S. It is also building a site in Virginia.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
September 23, 2025 13:33 ET (17:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
The 10 Best Companies to Invest in Now
10 Top-Performing US Dividend Stocks
United States